Tesis

Pengaruh jenis vaksin COVID-19 terhadap antibodi netralisasi berbagai varian SARS-CoV-2 = The Effect of COVID-19 Vaccine Types for Neutralizing Antibody Against SARSCoV-2 Variants.

Berbagai jenis vaksin COVID-19 akan mempengaruhi nilai antibodi netralisasi terhadap berbagai varian SARS-CoV-2. Evaluasi nilai antibodi netralisasi dilakukan pada kelompok penerima dosis primer lengkap (pra dan 28 hari pasca vaksinasi dosis primer lengkap) dan booster (pra, 28, dan 90 hari pasca booster). Riwayat infeksi SARS-CoV-2 pra-vaksinasi meningkatkan nilai antibodi netralisasi terhadap SARS-CoV-2 varian Wuhan, Delta, Omicron B.1.1.529, dan BA.2. Pemberian jenis vaksin dosis primer lengkap whole inactivated virus (Coronavac), non-replicating viral vector (AstraZeneca), dan mRNA (Pfizer) meningkatkan antibodi netralisasi 28 hari pasca vaksinasi terhadap SARS-CoV-2 varian Wuhan, Delta, Omicron B.1.1.529, dan BA.2. Pemberian dosis primer lengkap vaksin mRNA (Pfizer) paling meningkatkan antibodi netralisasi terhadap SARS-CoV-2 varian Omicron B.1.1.529 dan BA.2 dibandingkan dengan vaksin whole inactivated virus (Coronavac) dan non-replicating viral vector (AstraZeneca). Antibodi netralisasi juga dipengaruhi oleh jumlah total IgG anti-RBD SARS-CoV-2. Total IgG anti-RBD SARS-CoV-2 sebesar 100 BAU/mL sudah mampu menetralisasi 100% protein RBD pada vaksinasi dengan Pfizer, namun pada Coronavac dan AstraZeneca dibutuhkan total IgG anti-RBD yang lebih tinggi. Vaksinasi booster jenis mRNA (Moderna) meningkatkan nilai antibodi netralisasi terhadap berbagai varian SARS-CoV-2 jika dibandingkan dengan dosis primer lengkap vaksin jenis whole inactivated virus (Coronavac) (p < 0,05).
Kata kunci: Antibodi netralisasi, jenis vaksin COVID-19, varian SARS-CoV-2


Different types of COVID-19 vaccines will affect the value of neutralizing antibodies against various variants of SARS-CoV-2. Neutralizing antibody values were evaluated in the complete primary dose group (pre and 28 days after the complete primary dose vaccination) and booster (pre, 28, and 90 days post-booster). A history of pre-vaccination SARS-CoV-2 infection increased the value of neutralizing antibodies against SARS-CoV-2 variants of Wuhan, Delta, Omicron B.1.1.529, and BA.2. Administration of a complete primary dose of whole inactivated virus (Coronavac), non-replicating viral vector (AstraZeneca), and mRNA (Pfizer) vaccines increased neutralization antibodies 28 days after vaccination against SARS-CoV-2 variants of Wuhan, Delta, Omicron B.1.1.529, and BA.2. Administration of a complete primary dose of mRNA vaccine (Pfizer) increased neutralizing antibodies to SARS-CoV-2 variants Omicron B.1.1.529 and BA.2 the most compared to whole inactivated virus (Coronavac) and nonreplicating viral vector (AstraZeneca) vaccines. Neutralizing antibodies are also affected by the total amount of SARS-CoV-2 anti-RBD IgG. A total of 100 BAU/mL of SARS-CoV-2 anti-RBD IgG was able to neutralize 100% of the RBD protein in vaccination with Pfizer, but Coronavac and AstraZeneca required a higher total anti-RBD IgG. The mRNA booster vaccination (Moderna) increased the value of neutralizing antibodies against various variants of SARS-CoV-2 when compared to the complete primary dose of the whole inactivated virus vaccine (Coronavac) (p < 0.05).
Keywords: Neutralizing antibody, COVID-19 vaccines, SARS-CoV-2 variants